It has been proved that with the experimental calcitonin gene-related peptide (CGRP) antibody Erenumab can reduce the frequency of an episodic migraine — without the side effect profile which is commonly found with other migraine medications, suggest findings from two phase 3, randomised controlled clinical trials. CGRP plays an important role in the pathophysiology of migraine and this new human monoclonal antibody inhibits the CGRP receptor and efficacy is evaluated in these large multicenter double-blind placebo control and phase 3 clinical trials.
Trial 1 STRIVE TRIAL : Which assessed 955 adults with an episodic migraine, showed that patients who received subcutaneous monthly doses of Erenumab at 140 mg or 70 mg for 24 weeks had a significantly greater reduction in monthly migraine days (MMDs) compared with those who received matching placebo (the primary endpoint). Both dosing…
